- Home
- BKD vs KNSA Comparison
BKD vs KNSA Comparison
Compare BKD & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKD | KNSA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.4B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BKD | KNSA |
|---|---|---|
| Price | $14.45 | $46.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $13.10 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 5.0M | 595.3K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $0.41 | $38.01 |
| Revenue Next Year | $3.75 | $17.42 |
| P/E Ratio | ★ N/A | $61.29 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $4.97 | $18.26 |
| 52 Week High | $17.09 | $49.12 |
Technical Indicators
Market Signals| Indicator | BKD | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.71 | 57.86 |
| Support Level | $6.94 | $40.47 |
| Resistance Level | $17.09 | $49.12 |
| Average True Range (ATR) | 0.52 | 2.17 |
| MACD | -0.26 | 0.05 |
| Stochastic Oscillator | 19.39 | 71.13 |
Price Performance
Historical ComparisonAbout BKD Brookdale Senior Living Inc.
Brookdale Senior Living Inc operates senior living communities throughout the United States. The company has three reportable segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRs). The majority of the revenue is generated from the Assisted Living and Memory Care segment, which offers housing and assistance with activities of daily living to its customers. The company generates revenue in the form of Resident Fees, which it receives in exchange for the services provided, and in the form of management fees from certain communities under contract in exchange for the management services provided.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.